Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
383
-
Total 13F shares, excl. options
-
88.9M
-
Shares change
-
-1.47M
-
Total reported value, excl. options
-
$7.56B
-
Value change
-
-$136M
-
Put/Call ratio
-
1.17
-
Number of buys
-
185
-
Number of sells
-
-192
-
Price
-
$85.17
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q4 2021
471 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q4 2021.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 383 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 88.9M shares
of 99.6M outstanding shares and own 89.23% of the company stock.
Largest 10 shareholders include BlackRock Inc. (11.5M shares), VANGUARD GROUP INC (8.79M shares), JANUS HENDERSON GROUP PLC (7.45M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.36M shares), STATE STREET CORP (3.73M shares), Bellevue Group AG (3.18M shares), JPMORGAN CHASE & CO (2.98M shares), Bank of New York Mellon Corp (1.86M shares), EATON VANCE MANAGEMENT (1.85M shares), and GOLDMAN SACHS GROUP INC (1.52M shares).
This table shows the top 383 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.